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Severe allergic reactions following administration of Sugammadex with low 
tryptase levels but positive skin prick test: a case report 
 
Teške alergijske reakcije nakon primjene Sugammadexa s niskom razinom triptaze, ali 
pozitivnim testom uboda kože: prikaz slučaja 
 




We describe here the case of a severe anaphylactic episode to Sugammadex administered to reverse 
neuromuscular block in a 54-year-old man who underwent lumbar discectomy under general anaesthesia. 
Induction to anaesthesia and the entire surgical procedure were without any peculiarities. At the end of the 
surgery, 200 mg of Sugammadex was administered. Three minutes later, he developed a severe anaphylactic 
reaction accompanied by severe bronchospasm, with high peak airway pressures, drop of pulse oxygen 
saturation down to 70% despite FiO2 of 1.0, moderate decrease of arterial blood pressure (lowest was 80/50 
mmHg) and normal heart rate of 70/min. Also, five minutes later he developed generalized skin rash and 
piloerection. The patient recovered completely after initial medical treatment per guidelines for treatment of 
anaphylactic shock. He was extubated in the Intensivel Care Unit a few hours later. Repeated blood mastocyte 
tryptase levels showed only a mild increase during the acute reaction. The allergic reaction to Sugammadex 
was confirmed by a positive intradermal test to Sugammadex a couple months later. 




U radu opisujemo slučaj teške anafilaktičke reakcije na Sugammadex primijenjen u svrhu reverzije 
neuromišićnog bloka kod pedesetčetvorogodišnjeg muškarca tijekom lumbalne discektomije u općoj 
anesteziji. Uvod u anesteziju i sam operacijski postupak prošli su bez osobitosti. Na kraju operacijskog zahvata 
bolesnik je primio 200 mg Sugammadexa. Nakon tri minute po primjeni sredstva za reverziju bloka bolesnik 
je razvio tešku anafilaktičku reakciju praćenu teškim bronhospazmom, visokim tlakovima u dišnome krugu, 
padom saturacije periferne krvi kisikom do 70%, unatoč FiO2 1,0. Također, bolesnik je razvio umjereni pad 
krvnog arterijskog tlaka (najniža vrijednost bila je 80/50 mmHg), uz normalnu frekvenciju srčane akcije od 
70/min. Nadalje, 5 minuta nakon početne reakcije razvio je i generalizirani osip i piloerekciju. Bolesnik se 
ubrzo oporavio nakon početnog liječenja anafilaktičke reakcije po važećim smjernicama, te je ekstubiran u 
jedinici intenzivnog liječenja nekoliko sati kasnije. Laboratorijski uzorci za mastocitnu triptazu pokazali su 
samo blagi porast tijekom akutne reakcije. Alergijska reakcija na Sugammadex potvrđena je nekoliko mjeseci 
kasnije pozitivnim intradermalnim testiranjem.  
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Perioperative anaphylactic reactions are rare but 
potentially life-threatening events. The usual culprits 
are neuromuscular blocking agents, intravenous 
anaesthetics, opioids and non-steroidal anti-
inflammatory drugs. Diagnosis of anaphylaxis is based 
on clinical findings and elevated histamine and 
mastocyte tryptase levels. Anaphylactic reactions are 
immune mediated type I allergic reactions following 
the massive release of mediators from mast cells and 
basophils as a response to an allergen. Anaphylactoid 
reactions are defined as those reactions that produce 
the same clinical picture with anaphylaxis but are not 
IgE mediated, occur through a direct nonimmune-
mediated release of mediators from mast cells and/or 
basophils or result from direct complement activation.1 
The severity of allergic reactions can vary significantly. 
A recent gradation by Niggemann and Beyer suggested 
three grades: local reaction, mild to moderate systemic 
reaction (no cardiovascular and/or respiratory 
symptoms) and severe systemic allergic reaction 
(anaphylaxis) with cardiovascular and/or respiratory 
involvement.2  
Sugammadex is a newer neuromuscular blockade 
reversal agent. It acts by encapsulation of rocuronium 
or vecuronium molecules making them unavailable to 
the acetylcholine receptor at the neuromuscular 
junction. Sugammadex, unlike neostigmine, does not 
inhibit acetylcholinesterase, therefore co-administration 
of an antimuscarinic agent (glycopyrrolate or atropine) 
is not needed to prevent undesirable cholinergic effects 
and might have fewer adverse effects than the 
traditional reversal agents. Sugammadex has been 
approved for use in the European Union since 2008 by 
the European Medicines Agency (EMA). Due to 
concerns about its safety, the United States Food and 
Drug Administration (FDA) just recently approved the 
use of Sugammadex, which is generally considered a 
safe and well tolerated drug. Only a few cases of 
allergic reactions are described in the literature. We 
will describe a case of severe systemic allergic reaction 
to Sugammadex in a patient after lumbar spine surgery. 




A 54-year-old man (173 cm, 92 kg, BMI 31 kg/m2) 
underwent lumbar discectomy in a prone position. His 
medical history along with severe back pain was well 
controlled hypertension, high cholesterol, and asthma 
and with no history of allergies. His surgical history 
was only hernia surgery done under general anesthesia 
with no exposure to neuromuscular blocking agents 
(NMBA) nor reversal agents.  
General endotracheal anesthesia was induced with 
2 mg of midazolam (Midazolam, ADVANZ Pharma), 
100 mcg of fentanyl (Fentanyl, hameln pharma-
ceuticals ltd), 200 mg of propofol (Diprivan, Aspen) 
and 100 mg of rocuronium (Esmeron, Merck Sharp & 
Dohme Limited). After the induction, the patient 
received dexamethasone (8 mg) and ondansetron (4 
mg) for prophylaxis of postoperative nausea and 
vomiting, as well as tranexamic acid (1 g) for the 
prevention of acute blood loss during the surgery. Five 
milligrams of morphine were given for intraoperative 
pain control. Gentamicin (320 mg) and flucloxacillin 
(2 g) were given as prophylactic antibiotics. 
Sevoflurane in mixture of air and oxygen (50:50) with 
fresh gas flow of 1L/min was used for the maintenance 
of anesthesia. One hour after the induction, additional 
doses of fentanyl (100 mcg) and morphine were used 
for pain control. Also, 20 mg of rocuronium was given 
at the same time. Hartman’s solution was given for 
volume replacement. During the surgery, the patient 
was stable without any clinical problems. At the end of 
the surgery 1 g of vancomycin was locally applied to 
the wound and the wound was closed. The patient was 
flipped back to supine position and 200 mg of 
Sugammadex was administered for the reversal of 
neuromuscular blockade. Three minutes after 
Sugammadex administration we noticed severe 
bronchospasm, with high peak airway pressures, drop 
of pulse oxygen saturation down to 70% despite FiO2 
of 1.0, moderate decrease of BP (lowest was 80/50 
mmHg) and normal HR of 70/min. Also, five minutes 
later he developed generalized skin rash and 
piloerection. Immediately treatment of severe allergic 
reaction was started as with epinephrine 0.5 mg 
intramuscularly, 100 mg of hydrocortisone, 10 mg of 
chlorphenamine maleate and bolus of 1 L of Hartman’s 
was immediately infused. Due to severe wheezing, we 
administered 250 mg of aminophylline and 2 g 
magnesium sulphate in slow infusion. The patient 
responded to the initial treatment, but because of 
slowly resolving of bronchospasm he was sedated and 
remained intubated. Mechanical ventilation was 
continued in the critical care unit for the next few 
hours. He was haemodynamically stable and needed 
only epinephrine nebulizers for bronchoconstriction 
treatment for the next few hours until it was resolved. 
There was no need for intravenous vasopressors. Skin 
rash resolved 1 hour after intramuscular epinephrine 
injection which was given in the operation room. The 
patient completely recovered and was extubated that 
evening. Our patient’s symptoms would be Grade III-
severe systemic reaction = anaphylaxis.2  
Sugammadex was suspected as the allergic cause 
because no drug except Sugammadex was admi-
nistrated prior to development of the symptoms. 
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Blood samples were taken for mastocyte tryptase 
levels per guidelines for intraoperative anaphylaxis. 
Results were as follow: 1st sample (30 minutes after 
Sugammadex was given) 5.43 ng/L, 2nd sample (one 
hour later) 6.33 ng/L, 3rd sample (six hours later) 2.18 
ng/L, and 4th sample (3 days after an event) ˂  1.00 ng/L 
with normal values being below 11.5 ng/ml. Eight 
weeks later, allergy testing was performed. The skin 
Prick Test (SPT) and intradermal test (IDT) were 
negative for fentanyl, propofol, rocuronium, 
midazolam, ondansetron, dexamethasone, tranexamic 
acid, gentamicin and vancomycin, but the IDT was 
positive for Sugammadex (6 x 6 mm to 10 x 11 mm). 
Also, the patient tolerated the challenge to tranexamic 




Perioperative anaphylaxis is a life-threatening 
condition with an estimated prevalence of 1:3,500 to 1: 
20.000 procedures and a mortality rate of up to 9%.3  
Muscle relaxants and latex allergy account for most 
cases of anaphylaxis during the perioperative period.4 
Symptoms may include all organ systems and present 
with bronchospasm and cardiovascular collapse in the 
most severe cases.5 We have described severe 
anaphylactic reaction that occurred immediately after 
administration of 2.1 mg/kg of Sugammadex in a 
patient that underwent spinal surgery. Sugammadex 
was chosen due to fewer side effects and no need for 
anti-muscarinic agent co-administration.  
Sugammadex is rapidly replacing reversal of 
NMBA with neostigmine, where it is available, 
because of its safety profile. Hypersensitivity to 
Sugammadex is the major concern, but fortunately 
hypersensitivity reactions rarely occur.6 The US FDA 
postponed the approval of Sugammadex until 2015, 
citing concerns regarding its safety profile, including 
the risk of potentially life-threatening hypersensitivity 
reactions.7 A recent clinical trial did not show 
significantly different incidence of anaphylactic 
reactions between Sugammadex and placebo.8 
However, there are sporadic case reports of possible 
anaphylactic reactions caused by Sugammadex 
worldwide. The incidence of anaphylactic reactions 
caused by Sugammadex is much lower than that of 
anaphylaxis associated with neuromuscular blocking 
agents.8,9 Miyazaki and colleagues investigated 
retrospectively the incidence of potential 
Sugammadex-induced anaphylaxis at a single centre in 
Japan over a period of 3 years. They found that the 
overall incidence of intraoperative hypersensitivity 
reaction was 0.22%, and the incidence of anaphylaxis 
was only 0.059%.10 In a recent clinical study, Min and 
al. found that subjects who received Sugammadex with 
general anesthesia and/or NMB had a low overall 
incidence of hypersensitivity, with no apparent 
increase in hypersensitivity or anaphylaxis with 
Sugammadex as compared to placebo or neo-
stigmine.11  
Even though our patient had not been previously 
exposed to Sugammadex, development of allergic 
reaction was possible. Allergic reactions might occur 
due to cross-sensitivity to other drugs, foods, or 
common environmental chemicals.12 Also, our patient 
had a history of well controlled asthma which could 
increase the risk for severe allergic reaction. He 
developed mostly respiratory symptoms with only a 
mild decrease of blood pressure and normal heart rate. 
Prompt treatment with epinephrine and fluid loading 
are probable reasons for preserved cardiovascular 
stability. Additionally, our patient was a middle aged 
man who was fit and well before surgery with no 
cardiac symptoms and good exercise tolerance and, 
therefore, more capable to compensate cardiovascular 
changes during anaphylactic reaction. The diagnosis of 
anaphylaxis is based on suggestive clinical symptoms 
after exposure to a potential triggering agent or event. 
Currently, there is no reliable biological marker 
available to confirm the diagnosis.13 It can be only 
supported by laboratory tests, such as histamine or 
tryptase levels. These mediators are contained in the 
mast cells and they are released into circulation after 
mast cell activation.13 Serum tryptase concentration is 
the most used laboratory test to confirm anaphylaxis, 
still normal levels do not refuse diagnosis. Current 
recommendation from literature is serial measure-
ments of tryptase levels because of higher sensitivity 
and specificity.14 Despite the typical clinical picture of 
anaphylactic reaction, tryptase levels in our patient 
remained within normal range (less than 11.5 ng/mL), 
but still showed changes over the time. Our diagnosis 
is supported by decreasing of tryptase levels below 1 
ng/mL three days after anaphylactic reaction (baseline 
level). Studies on drug-induced anaphylactic reactions 
suggest that milder allergic reactions may be 
associated with no increase in the tryptase levels.15 
Allergy tests of our patient showed positive result on 
intradermal test (IDT) only for Sugammadex, 




Clinicians must be aware that severe anaphylactic 
reactions can be induced by the administration of 
Sugammadex, even with patients with no previous 
exposure. Diagnosis is still based on typical clinical 
features, and laboratory tests are only supportive. 
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